# Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors

> **NCT02658214** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 32 (actual)

## Conditions studied

- Small Cell Lung Carcinoma
- Carcinoma, Squamous Cell of Head and Neck
- Stomach Neoplasms
- Triple Negative Breast Neoplasms
- Ovarian Neoplasms
- Fallopian Tube Neoplasms
- Peritoneal Neoplasms
- Esophagogastric Junction Neoplasms
- Carcinoma, Pancreatic Ductal
- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** paclitaxel + carboplatin
- **DRUG:** carboplatin + etoposide
- **DRUG:** gemcitabine + carboplatin
- **DRUG:** nab-paclitaxel (paclitaxel-albumin) + carboplatin
- **DRUG:** oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)
- **BIOLOGICAL:** durvalumab
- **BIOLOGICAL:** tremelimumab
- **DRUG:** nab-paclitaxel (paclitaxel-albumin) + gemcitabine
- **DRUG:** cisplatin + 5-fluorouracil (5FU)

## Key facts

- **NCT ID:** NCT02658214
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04-28
- **Primary completion:** 2019-11-14
- **Final completion:** 2019-11-14
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02658214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02658214, "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02658214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*